請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67524
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李明學(Ming-Shyue Lee) | |
dc.contributor.author | Yu-chi Yu | en |
dc.contributor.author | 尤鈺淇 | zh_TW |
dc.date.accessioned | 2021-06-17T01:36:00Z | - |
dc.date.available | 2027-08-01 | |
dc.date.copyright | 2017-09-08 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-01 | |
dc.identifier.citation | 1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7-30
2. 台灣衛生福利部國民健康署. 民國104年死因統計結果分析. 2016 3. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913-21 4. Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2016;30:355-85 5. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nature Reviews Disease Primers 2016;2:16022 6. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267 7. Bachmann J, Michalski CW, Martignoni ME, Buchler MW, Friess H. Pancreatic resection for pancreatic cancer. HPB (Oxford) 2006;8:346-51 8. Gnanamony M, Gondi CS. Chemoresistance in pancreatic cancer: Emerging concepts. Oncol Lett 2017;13:2507-13 9. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. The Lancet 2016;388:73-85 10. Steeg PS. Targeting metastasis. Nat Rev Cancer 2016;16:201-18 11. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell 2000;100:57-70 12. Leber MF, Efferth T. Molecular principles of cancer invasion and metastasis (review). Int J Oncol 2009;34:881-95 13. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003;22:6524-36 14. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006;6:449-58 15. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67 16. Cao J, Cai X, Zheng L, Geng L, Shi Z, Pao CC, et al. Characterization of colorectal-cancer-related cDNA clones obtained by subtractive hybridization screening. J Cancer Res Clin Oncol 1997;123:447-51 17. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proceedings of the National Academy of Sciences of the United States of America 1999;96:11054-61 18. Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, Wang Y, Yan Y, et al. The matrix metalloprotease pump-1 (MMP-7, Matrilysin): A candidate marker/target for ovarian cancer detection and treatment. Tumour Biol 1999;20:88-98 19. Shi YE, Torri J, Yieh L, Wellstein A, Lippman ME, Dickson RB. Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res 1993;53:1409-15 20. Lee M-S. Matrix-Degrading Type II Transmembrane Serine Protease Matriptase: Its Role in Cancer Development and Malignancy. J Cancer Mol 2006;2:183-90 21. Oberst M, Anders J, Xie B, Singh B, Ossandon M, Johnson M, et al. Matriptase and HAI-1 Are Expressed by Normal and Malignant Epithelial Cells in Vitro and in Vivo. The American Journal of Pathology 2001;158:1301-11 22. Kojima K, Inouye K. Activation of matriptase zymogen. J Biochem 2011;150:123-5 23. List K, Bugge TH, Szabo R. Matriptase: potent proteolysis on the cell surface. Molecular medicine (Cambridge, Mass 2006;12:1-7 24. Tseng IC, Xu H, Chou FP, Li G, Vazzano AP, Kao JP, et al. Matriptase activation, an early cellular response to acidosis. J Biol Chem 2010;285:3261-70 25. List K. Matriptase: a culprit in cancer? Future Oncol 2009;5:97-104 26. Mars WM, Zarnegar R, Michalopoulos GK. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 1993;143:949-58 27. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000;275:26333-42 28. Seitz I, Hess S, Schulz H, Eckl R, Busch G, Montens HP, et al. Membrane-type serine protease-1/matriptase induces interleukin-6 and -8 in endothelial cells by activation of protease-activated receptor-2: potential implications in atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:769-75 29. Jin X, Yagi M, Akiyama N, Hirosaki T, Higashi S, Lin CY, et al. Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci 2006;97:1327-34 30. Netzel-Arnett S, Currie BM, Szabo R, Lin CY, Chen LM, Chai KX, et al. Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Biol Chem 2006;281:32941-5 31. Ahmed S, Jin X, Yagi M, Yasuda C, Sato Y, Higashi S, et al. Identification of membrane-bound serine proteinase matriptase as processing enzyme of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/angiomodulin/mac25). FEBS J 2006;273:615-27 32. KERSTIN UHLAND BS, CHRISTOPH ARKONA, MAJ SCHUSTER, BERNHARD PETRI, PETER STEINMETZER, FRIEDEMANN MUELLER, NDREA SCHWEINITZ, TORSTEN STEINMETZER and ANDREAS VAN DE LOCHT. Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma. INTERNATIONAL JOURNAL OF ONCOLOGY 2009;35:347-57 33. Winslow LC, Kroll DJ. Herbs as medicines. Arch Intern Med 1998;158:2192-9 34. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol 2005;100:72-9 35. Teschke R, Wolff A, Frenzel C, Schulze J. Review article: Herbal hepatotoxicity--an update on traditional Chinese medicine preparations. Aliment Pharmacol Ther 2014;40:32-50 36. Ng SC, Lam YT, Tsoi KK, Chan FK, Sung JJ, Wu JC. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013;38:854-63 37. Craig WJ. Health-promoting properties of common herbs. Am J Clin Nutr 1999;70:491S-9S 38. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001;286:208-16 39. Lin CC, Lin JM, Chiu HF. Studies on folk medicine 'thang-kau-tin' from Taiwan. (I). The anti-inflammatory and liver-protective effect. Am J Chin Med 1992;20:37-50 40. Lin JM, Lin CC, Chen MF, Ujiie T, Takada A. Studies on Taiwan folk medicine, thang-kau-tin (II): Measurement of active oxygen scavenging activity using an ESR technique. Am J Chin Med 1995;23:43-51 41. Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (mia paca-2) in continuous culture: Sensitivity to asparaginase. International Journal of Cancer 1977;19:128-35 42. Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, Scaife CL, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas 2010;39:425-35 43. Jagadeeshwar Rao R, Tiwari AK, Kumar US, Reddy SV, Ali AZ, Rao JM. Novel 3-O-acyl mesquitol analogues as free-radical scavengers and enzyme inhibitors: synthesis, biological evaluation and structure-activity relationship. Bioorg Med Chem Lett 2003;13:2777-80 44. Sirmah P, Dumarcay S, Masson E, Gerardin P. Unusual amount of (-)-mesquitol from the heartwood of Prosopis juliflora. Nat Prod Res 2009;23:183-9 45. Sirmah P, Mburu F, Iaych K, Dumar, xe, ay S, et al. POTENTIAL ANTIOXIDANT COMPOUNDS FROM DIFFERENT PARTS OF PROSOPIS JULIFLORA. Journal of Tropical Forest Science 2011;23:187-95 46. Ferrari F, Messana I, Botta B, de Mello JF. Constituents of Guettarda platypoda. Journal of Natural Products 1986;49:1150-1 47. Kitajima M, Hashimoto K, Yokoya M, Takayama H, Aimi N, Sakai SI. A new gluco indole alkaloid, 3, 4-dehydro-5-carboxystrictosidine, from Peruvian Una de Gato (Uncaria tomentosa). Chem Pharm Bull (Tokyo) 2000;48:1410-2 48. Liu Z, Cheng Z, He Q, Lin B, Gao P, Li L, et al. Secondary metabolites from the flower buds of Lonicera japonica and their in vitro anti-diabetic activities. Fitoterapia 2016;110:44-51 49. Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 2014;260:372-7 50. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903 51. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006;10:1199-210; discussion 210-1 52. Suresh G, Tiwari AK, Radha Krishna Murthy M, Anand Kumar D, Rajendra Prasad K, Ranga Rao R, et al. New advanced glycation end-products inhibitors from Dichrostachys cinerea Wight & Arn. J Nat Med 2012;66:213-6 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67524 | - |
dc.description.abstract | 胰臟癌是目前最惡性的癌症之一,且治療效果非常不佳,病患的五年存活率低於5%。胰臟癌如此高的死亡率歸咎於其高侵襲轉移力,且癌症初期並無太多症狀,容易被疏忽,當被確診時大多已經轉移至淋巴及肝臟等其他臟器。目前主要用來治療轉移性癌症的療法是化學療法,但病患接受化學治療時,容易有嚴重的副作用。因此發展能有效抑制胰臟癌細胞侵襲能力且具低毒性、低副作用的藥物,是相當迫切更有其必要性。在先前的研究中,我們發現NTU04能夠抑制肝癌細胞侵襲力。我們進一步在台灣找到與NTU04同屬的植物(MSL-UH),並利用酒精萃取,發現MSL-UH使用液相層析分離出的F3和F4具有明顯抑制胰臟癌細胞侵襲能力的效果。在我的研究中,我們將F3和F4進一步分離出F3-4、F3-5、F4-1、F4-2和F4-3有較好的抑制癌細胞侵襲能力的活性的子分層,並將這些子分層收集命名為UH3443,發現UH3443在抑制胰腺癌細胞的侵襲力上有顯著的效果。此外,我們純化出UH3443中最主要的三個化合物(peak 1, 2 and 4),並且使用質譜儀與核磁共振儀測定解其分子結構。雖然這三個化合物在單獨的狀況下無法有效抑制胰臟癌細胞的侵襲能力,但是我們發現這三個主要化合物的組合能夠顯著的抑制PANC-1細胞約一半的侵襲力。綜合以上結果我們發現UH3443中所分離出來的三種化合物組合在抑制胰腺癌侵襲上相當具有潛力的。 | zh_TW |
dc.description.abstract | Pancreatic cancer (PCa) is one of the most malignant cancers and has a low 5-year survival rate of 4-6%. The PCa high mortality is attributed to its highly invasive and metastatic capability. Chemotherapy is commonly used for the treatment of metastatic PCa; however, this treatment often causes patients severe side effects. Thus, developing a new medication to suppress PCa cell invasion, metastasis and progression with low toxicity is critically needed. In our previous study, we found herbal extract NTU04 could suppress the invasion ability of hepatic cancer cells, and then prepared the herbal extract (MSL-UH) from a local herb in Taiwan, which belongs to the same genus to NTU04. Moreover, we found that the fractions F3 and F4 of MSL-UH were effective to suppress PCa cell invasion. In this study, I further identify the more effective subfractions from F3 and F4, and found that the subfractions (F3-4, F3-5, F4-1, F4-2 and F4-3, named as UH3443) had a better suppressive activity than F3 and F4. Moreover, I purified the compounds in the four major peaks (1~4) in UH3443 and the compound structures in peak 1, 2 and 4 were identified. Although individual compounds in peak 1, 2 and 4 had no effect on the cell invasion, the combination effect of these 3 compounds could inhibit PCa cell invasion by approximately 50%. The results indicate that UH3443 and the three-compound mixture can serve as a potential herbal product to suppress PCa cell motility. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T01:36:00Z (GMT). No. of bitstreams: 1 ntu-106-R04442024-1.pdf: 3554742 bytes, checksum: 4c3422243e50dd850e1aa04ab2d0cab4 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 致謝.……………………………………………………………………………………I
摘要.…………………………………………………………………………………..II Abstract……………………………………………………………………………...III Chapter1. Introduction 1 1.1 Pancreatic cancer 2 1.2 Cancer metastasis 3 1.3 Herbal extracts: MSL-UH 6 1.4 Research motivation 7 Chapter2. Materials and Methods 9 2.1 Materials 10 2.2 Methods 15 Chapter3. Results 27 3.1 Preparation of UH3443 from herbal extracts MSL-UH 28 3.2 Effects of UH3443 on the viabilities and invasive abilities of PDAC cells. …………………………………………………………………………..28 3.3 Effects of UH3443 on the protein and mRNA expression levels of matriptase in Capan-1 cells. 29 3.4 Effects of UH3443 on the proteins and mRNA level of matriptase in matriptase-overexpressing PANC-1 cells. 31 3.5 Purification and identification of effective compounds in UH3443. 32 3.6 Effects of the three compounds purified from UH3443 on PDAC cell invasion 33 3.7 Effects of the compounds purified from UH3443 on PDAC cell invasion. …………………………………………………………………………..34 Chapter4. Discussion 35 Chapter5. Figures 40 Chapter6. References 59 | |
dc.language.iso | en | |
dc.title | 草藥萃取物UH3443抑制胰腺癌侵襲力之研究 | zh_TW |
dc.title | Herbal extracts UH3443 suppress pancreatic ductal adenocarcinoma cell invasion | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 符文美(Wen-Mei Fu),顧記華(Jih-Hwa Guh),蕭培文(Pei-Wen Hsiao) | |
dc.subject.keyword | 胰腺癌,中草藥,侵襲力, | zh_TW |
dc.subject.keyword | Pancreatic cancer,Herbal extracts,Invasion, | en |
dc.relation.page | 63 | |
dc.identifier.doi | 10.6342/NTU201702314 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-08-01 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 3.47 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。